Certa Therapeutics

Certa Therapeutics is a Melbourne-based biotechnology company developing innovative precision therapies for fibrotic diseases. Their lead program, asengeprast (FT011), is an oral GPR68 antagonist targeting systemic sclerosis and chronic kidney disease. The company is backed by venture investors Brandon Capital and Uniseed.

• Biotech